| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/23/2013 | WO2013073642A1 Gel of reduced pyrroloquinoline quinone |
| 05/23/2013 | WO2013073620A1 Carotenoid-containing composition and method for producing same |
| 05/23/2013 | WO2013073454A2 Controlled release composition for physiologically active substance |
| 05/23/2013 | WO2013072937A2 Fast release solid oral compositions of entecavir |
| 05/23/2013 | WO2013072770A2 Pharmaceutical formulations comprising atorvastatin and glimepiride |
| 05/23/2013 | WO2013072767A1 Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| 05/23/2013 | WO2013072707A1 Treatment of adrenal insufficiency |
| 05/23/2013 | WO2013072686A2 Self-assembling peptides |
| 05/23/2013 | WO2013072676A1 Film-forming formulation |
| 05/23/2013 | WO2013072563A1 Drug delivery system for sustained delivery of bioactive agents |
| 05/23/2013 | WO2013072545A1 Mixed nanoparticles for controlled release of active principles |
| 05/23/2013 | WO2013072395A1 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 05/23/2013 | WO2013072329A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/23/2013 | WO2013072304A1 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 |
| 05/23/2013 | WO2013072290A1 Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents |
| 05/23/2013 | WO2013072062A1 Composition for transdermal administration of rivastigmine |
| 05/23/2013 | WO2013072051A1 Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| 05/23/2013 | WO2013071696A1 Use of five normal bases in humans for preparation of tumour drugs |
| 05/23/2013 | WO2013071457A1 Injectable veterinary composition for controlled, sustained release of ceftiofur and florfenicol in animal species, based on polyhydroxybutyrate hydroxyvalerate (phbv) microparticles |
| 05/23/2013 | WO2013071456A2 Injectable veterinary composition for sustained release of ceftiofur and florfenicol in animal species, which comprises poly(lacticcoglycolic acid) (plga) microparticles, and the method for the preparation thereof |
| 05/23/2013 | WO2013071421A1 Pharmaceutical composition of amphetamine mixed salts |
| 05/23/2013 | WO2013059617A9 Liposome compositions and methods of use |
| 05/23/2013 | WO2013049531A3 Multilayer magnetic micelle compositions and methods for their use |
| 05/23/2013 | WO2013044203A3 Novel influenza hemagglutinin protein-based vaccines |
| 05/23/2013 | WO2013037487A8 A particulate system for use in diminishing cell growth/inducing cell killing |
| 05/23/2013 | WO2012125408A8 Pegylated apelin and uses thereof |
| 05/23/2013 | US20130131630 Programmable insulin pump |
| 05/23/2013 | US20130131628 Device and method for sustained release of therapeutic agent |
| 05/23/2013 | US20130131621 Dressing device |
| 05/23/2013 | US20130131333 Cellulose interpolymers and method of oxidation |
| 05/23/2013 | US20130131191 Additive for tablets |
| 05/23/2013 | US20130131186 Microemulsion Preparation of High Concentration Propofol for Anesthetic Uses |
| 05/23/2013 | US20130131166 Bioadhesive compositions for epithelial drug delivery |
| 05/23/2013 | US20130131142 Rna interference in ocular indications |
| 05/23/2013 | US20130131125 Therapeutic combination |
| 05/23/2013 | US20130131123 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 05/23/2013 | US20130131098 Pharmaceutical formulation of apomorphine for buccal administration |
| 05/23/2013 | US20130131089 Dosage forms of elinogrel and methods of injectable administration thereof |
| 05/23/2013 | US20130131052 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases |
| 05/23/2013 | US20130131029 Antisolvent solidification process |
| 05/23/2013 | US20130131027 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis |
| 05/23/2013 | US20130130977 Polymer-based sustained release device |
| 05/23/2013 | US20130130910 Sustained release microparticles and sustained release microparticle-containing preparations |
| 05/23/2013 | US20130129830 Polymer Protein Microparticles |
| 05/23/2013 | US20130129829 Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules |
| 05/23/2013 | US20130129828 Compositions and methods for delivery of poorly soluble drugs |
| 05/23/2013 | US20130129827 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| 05/23/2013 | US20130129825 Diversion-resistant microgranules and microtablets |
| 05/23/2013 | US20130129824 Solid Drug Tablets for Implantable Drug Delivery Devices |
| 05/23/2013 | US20130129823 Pharmaceutical compositions for glucocorticoid replacement therapy |
| 05/23/2013 | US20130129822 Liquid-filled hard gel capsule pharmaceutical formulations |
| 05/23/2013 | US20130129818 Natural combination hormone replacement formulations and therapies |
| 05/23/2013 | US20130129817 Method of treating malignant solid tumors |
| 05/23/2013 | US20130129816 Therapeutic composition with enhanced endothelium targeting |
| 05/23/2013 | US20130129815 Liposomal formulation for oral administration of glutathione (reduced) via gel capsule |
| 05/23/2013 | US20130129808 Medical product containing active component of propolis or grapefruit seed extract and manufacturing method thereof |
| 05/23/2013 | US20130129807 Collagen-based implants for sustained delivery of drugs |
| 05/23/2013 | US20130129801 Aqueous dispersion comprising galactolipids and method for production thereof |
| 05/23/2013 | US20130129798 Extended-Release Composition Comprising a Somatostatin Derivative in Microparticles |
| 05/23/2013 | US20130129792 Pharmacokinetics of S-Adenosylmethionine Formulations |
| 05/23/2013 | US20130129791 Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof |
| 05/23/2013 | US20130129789 Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| 05/23/2013 | US20130129786 Hydrophilic filtration during manufacture of vaccine adjuvants |
| 05/23/2013 | US20130129781 Methods and compositions for intranasal delivery |
| 05/23/2013 | US20130129691 Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same |
| 05/23/2013 | US20130129640 Compressed Chewing Gum |
| 05/23/2013 | US20130129618 Egcg stabilized gold nanoparticles and method for making same |
| 05/23/2013 | US20130129616 Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue |
| 05/23/2013 | US20130125884 Novel dosage and formulation |
| 05/23/2013 | CA2856243A1 Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| 05/23/2013 | CA2856074A1 Autoclavable suspensions of cyclosporin a form 2 |
| 05/23/2013 | CA2856057A1 Suspensions of cyclosporin a form 2 |
| 05/23/2013 | CA2856044A1 Sustained action formulation of cyclosporin form 2 |
| 05/23/2013 | CA2856016A1 Agent for treating fibrosis of the intestine |
| 05/23/2013 | CA2855749A1 Polymer protein microparticles |
| 05/23/2013 | CA2855718A1 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 05/23/2013 | CA2855503A1 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
| 05/23/2013 | CA2854717A1 Treatment of adrenal insufficiency |
| 05/23/2013 | CA2853880A1 Single-dose pharmaceutical preparation of thyroid hormones t3 and/or t4 |
| 05/23/2013 | CA2851209A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/22/2013 | EP2594920A1 Spread analysis device for lubricant, method, and program |
| 05/22/2013 | EP2594313A2 Hollow microneedle having a variable appearance |
| 05/22/2013 | EP2594283A1 Aprotinin-based aerosol preparation for the treatment of viral respiratory infections |
| 05/22/2013 | EP2594281A1 Insulin-lipid complex, preparation method therefor, and preparation thereof |
| 05/22/2013 | EP2594278A1 Film, patch or adhesive solid formulation comprising Sambucus nigra, Centella asiatica and 1-alkylpyridinium salt for the treatment of mucosal tissue. |
| 05/22/2013 | EP2594277A1 Tablet containing ferric citrate |
| 05/22/2013 | EP2594272A2 Aerosolized fluoroquinolones and uses thereof |
| 05/22/2013 | EP2594271A1 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| 05/22/2013 | EP2594269A1 Controlled release nucleated tablet |
| 05/22/2013 | EP2594266A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/22/2013 | EP2594263A2 Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins |
| 05/22/2013 | EP2594262A1 Substrate of three-layer structure and water-containing adhesive patch including same |
| 05/22/2013 | EP2594261A1 Composition for transdermal administration of rivastigmine |
| 05/22/2013 | EP2594260A1 Solid preparations comprising sirolimus with desired bioavailability and method for its preparation |
| 05/22/2013 | EP2594259A1 Methods for manufacturing delivery devices and devices thereof |
| 05/22/2013 | EP2594258A1 Oral gel comprising praziquantel |
| 05/22/2013 | EP2594257A1 Orodispersible films for the manufacturing of individualised medicine or for large scale production |
| 05/22/2013 | EP2594254A1 Oil-based gel-like composition |
| 05/22/2013 | EP2593463A1 Formulations of rifaximin and uses thereof |
| 05/22/2013 | EP2593131A2 Methods and compositions for cns delivery of iduronate-2-sulfatase |